Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00983268
Other study ID # VICC GI 0934
Secondary ID P30CA068485VU-VI
Status Completed
Phase Phase 1
First received September 23, 2009
Last updated June 11, 2015
Start date October 2009
Est. completion date February 2013

Study information

Verified date June 2015
Source Vanderbilt-Ingram Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving capecitabine and vorinostat together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with capecitabine and radiation therapy in treating patients with nonmetastatic pancreatic cancer.


Description:

OBJECTIVES:

Primary

- Determine the maximum tolerated dose of vorinostat when given in combination with capecitabine and high-dose hypofractionated radiotherapy in patients with nonmetastatic pancreatic cancer.

Secondary

- Determine the safety and side effect profile of this regimen in these patients.

- Determine the response rate in patients treated with this regimen.

Correlative

- Compare pre- and post-treatment whole-cell HDAC-activity levels in peripheral blood mononuclear cell samples.

- Assess chromatin structure and DNA damage in surgical tumor tissue samples.

- Assess proliferation and apoptosis by in vivo imaging.

OUTLINE: This is a dose-escalation study of vorinostat.

Patients receive oral capecitabine twice daily and undergo high-dose hypofractionated radiotherapy once daily on days 1-5 and 8-12. Patients also receive oral vorinostat once daily on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity.

Patients are evaluated for surgery within 6 weeks after completion of chemoradiotherapy. Patients with resectable disease proceed to surgery. Patients with unresectable disease may receive oral vorinostat once daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for correlative laboratory studies. Patients also undergo diffusion-weighted MRI for analysis of in vivo tumor cellularity.

After completion of study therapy, patients are followed up periodically for 5 years.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date February 2013
Est. primary completion date February 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient must have histologically confirmed pancreatic or periampullary cancer.

- Patient must be > 18 years of age.

- Patient may be resectable, borderline resectable, or unresectable but locally advanced as determined by radiographic examination and consultation with a surgical oncologist.

- Patient must have Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

- Female patients of childbearing potential must be willing to use birth control. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy, used throughout the study starting with visit 1. The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner) or sponge. Other methods of contraception such as copper intrauterine device or spermicide may be used. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).Female patient of childbearing potential has a negative serum pregnancy test ß-hCG within 7 days prior to receiving the first dose of vorinostat.

- Male patients agree to use an adequate method of contraception for the duration of the study.

- Patient has a life expectancy of at least 12 weeks

- Patient must have adequate organ function as indicated by the following laboratory values:

- Absolute neutrophil count (ANC) =1,500 /mcL

- Platelets =100,000 / mcL Hemoglobin = 9 g/dL

- Coagulation

- Prothrombin Time or INR =1.5x upper limit of normal (ULN) unless receiving therapeutic anticoagulation

- Partial thromboplastin time (PTT) =1.2 times the ULN unless the patient is receiving therapeutic anticoagulation.

- K levels - Normal limits

- Mg levels - Normal limits

- Calculated creatinine *clearance =20 mL/min

- Serum total bilirubin = 1.5 X ULN

- AST (SGOT) and ALT (SGPT) = 2.5 X ULN

- Alkaline Phosphatase = 2.5 X ULN

* Creatinine clearance should be calculated per institutional standard.

- Patient must be capable of understanding and complying with the study protocol and able to give informed consent.

- Measurable disease is not an eligibility requirement.

Exclusion Criteria:

- Prior chemotherapy for pancreatic or periampullary cancer.

- Prior radiation to any area within the planned radiation field. All patients with history of prior radiation to any area must be approved by PI.

- Evidence of distant metastases on imaging.

- History of hypersensitivity to fluoropyrimidines or HDACs.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
capecitabine
1000 mg taken by mouth on the days of radiation only.
vorinostat
Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses: Vorinostat,at 100 mg Vorinostat,at 200 mg Vorinostat, at 300 mg Vorinostat, at 400 mg
Radiation:
Radiotherapy
High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
Procedure:
Surgery to remove tumor
Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.

Locations

Country Name City State
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee

Sponsors (3)

Lead Sponsor Collaborator
Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI), National Comprehensive Cancer Network

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of vorinostat when given in combination with capecitabine and radiotherapy Two weeks after completing radiotherapy Yes
Secondary Toxicity as assessed by NCI CTCAE v3.0 Six weeks after completing chemo-radiation therpay Yes
Secondary Tumor response as assessed by RECIST criteria Six weeks after completing chemo-radiation therpay No
Secondary Biological effect Six weeks after completing chemo-radiation therapy No
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study